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Summary
 
B cell receptor (BCR)-mediated antigen processing is a mechanism that allows class II–restricted
presentation of specific antigen by B cells at relatively low antigen concentrations. Although
BCR-mediated antigen processing and class II peptide loading may occur within one or more
endocytic compartments, the functions of these compartments and their relationships to endo-
somes and lysosomes remain uncertain. In murine B cells, at least one population of class II–
containing endocytic vesicles (i.e., CIIV) has been identified and demonstrated to be distinct
both physically and functionally from endosomes and lysosomes. We now demonstrate the de-
livery of BCR-internalized antigen to CIIV within the time frame during which BCR-medi-
ated antigen processing and formation of peptide–class II complexes occurs. Only a fraction of
the BCR-internalized antigen was delivered to CIIV, with the majority of internalized antigen
being delivered to lysosomes that are largely class II negative. The extensive colocalization of
BCR-internalized antigen and newly synthesized class II molecules in CIIV suggests that CIIV
may represent a specialized subcellular compartment for BCR-mediated antigen processing.
Additionally, we have identified a putative CIIV-marker protein, immunologically related to the
Ig
 
a
 
 subunit of the BCR, which further illustrates the unique nature of these endocytic vesicles.
 
T
 
he recognition of MHC class II–restricted antigens by
antigen-specific T cells requires the proteolytic pro-
cessing of protein antigens to immunogenic peptides by
class II–positive antigen-presenting cells (1, 2). The first
step in antigen processing by B cells involves B cell receptor
(BCR)
 
1
 
–mediated internalization of antigen (3–5). BCR-
internalized antigen is then proteolytically processed and
the resultant peptides preferentially loaded onto newly syn-
thesized class II molecules (6–8) from which the class II–
associated invariant chain has been removed by the con-
certed action of acid proteases and the protein HLA-DM/
H-2M (9). The resultant peptide–class II complexes are
then transported to the surface of the B cell.
The intracellular compartments where antigen process-
ing occurs have only recently been characterized and there
is considerable variation in the intracellular localization of
class II molecules among different cell types. Many cells,
such as human lymphoblasts and macrophages, sequester
much of their class II in lysosomes or lysosome-like struc-
tures referred to as the MHC class II–enriched compart-
ment (MIIC; reference 10). Although delivery of BCR-
internalized antigen to MIIC has been demonstrated (11),
the fate of the antigen delivered to these structures (i.e., com-
plete degradation versus processing and binding to class II
molecules) remains unknown.
In other professional antigen-presenting cells such as
many murine B cell lines, there is little accumulation of
class II in lysosomes under normal conditions (12–14). In-
stead, class II is found in endosomes and endosome-related
structures, at least one population of which (class II vesicles
[CIIV]) can be purified and physically separated from con-
ventional endocytic and secretory organelles by cell frac-
tionation techniques (14).
Although many or all endocytic, class II–containing ves-
icle populations may host the loading of peptides onto class
II molecules, there may be important qualitative differences
regarding the subcellular compartments where antigenic
peptides are generated and efficiently loaded onto class II
molecules. Specifically, although BCR-mediated antigen
 
1
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presentation appears to involve binding of peptide to newly
synthesized class II molecules (6–8), presentation of fluid
phase proteins by B cells appears to be able to occur via
both newly synthesized and recycling class II molecules (7,
8, 15, 16), possibly reflecting differences in the intracellular
sites of peptide generation and class II loading.
Additionally, not all receptors are equivalent at mediating
antigen processing and presentation. In murine B cells, an-
tigen internalized via the transferrin receptor (while pre-
sented more efficiently than soluble antigen) is presented
10–100 times less efficiently than the same antigen internal-
ized via the BCR (17). This result may reflect the fact that
the transferrin receptor has far more restricted access to in-
tracellular class II compartments in B cells than does the
BCR (11). Even more dramatic is the demonstration that a
single amino acid substitution in the transmembrane region
of the human IgM BCR (huBCR) can completely abolish
the ability of this receptor to mediate efficient antigen pro-
cessing and presentation without affecting BCR-mediated
antigen endocytosis and bulk antigen degradation (18, 19).
Thus, antigen uptake and degradation is necessary, but not
sufficient, for antigen processing and presentation.
Thus, it has become important to determine the intracel-
lular compartments to which physiologically important re-
ceptors (e.g., the BCR) deliver antigens. In this paper, we
demonstrate that, within the time frame during which the
intracellular events of BCR-mediated antigen processing
are known to occur, BCR molecules and BCR-internal-
ized antigen have access not only to predominantly class II–
negative endosome and lysosomes, but also to a novel pop-
ulation of endocytic vesicles that are highly enriched in
newly synthesized class II molecules (i.e., CIIV). More-
over, CIIV contain a putative marker protein, immunolog-
ically related to the Ig
 
a
 
 subunit of the BCR, further illus-
trating the distinct nature of these endocytic vesicles.
 
Materials and Methods
 
Cell Culture and Fractionation.
 
A20
 
m
 
WT (i.e., A20 cells ex-
pressing a transfected, phosphorylcholine (PC)–specific human
mIgM BCR (huBCR); reference 19) were cultured in 
 
a
 
MEM,
5% FBS, 50 
 
m
 
M 2-mercaptoethanol, and 500 
 
m
 
g/ml G418.
A20
 
m
 
WT cells were homogenized, fractionated by free flow
electrophoresis (FFE), and the distribution of plasma membrane,
lysosomes, and CIIV was determined as previously reported (14).
 
Distribution of huBCR-internalized Antigen in A20
 
m
 
WT FFE
Fractions.
 
A20
 
m
 
WT cells (2 
 
3
 
 10
 
8
 
 total cells) were incubated at
4 
 
3
 
 10
 
7
 
 cells/ml for 30 min at 37
 
8
 
C in media containing 2 
 
m
 
g/ml
PC-modified Fab fragments of rabbit 
 
g
 
 globulin labeled with 
 
125
 
I
(PC–RGG–
 
125
 
I [2
 
m
 
Ci 
 
125
 
I/
 
m
 
g PC–RGG]), homogenized, frac-
tionated by FFE, and the distribution of the plasma membrane
and lysosomes was determined. The distribution of PC–RGG–
 
125
 
I
was determined by counting each FFE fraction in a 
 
g
 
 counter.
Background counts (
 
,
 
100 cpm) were subtracted from the counts
for each sample and the results normalized to a maximum value
of 1.00.
 
Immuno-electron Microscopy Localization of huBCR-internalized
Antigen and BCR Molecules to Isolated CIIV.
 
A20
 
m
 
WT cells were
incubated in 400-nM PC-modified ovalbumin (PC–OVA) for 20
min at 37
 
8
 
C, homogenized, and fractionated by FFE. Isolated
CIIV, as well as endosomes–lysosomes, were processed for im-
muno-electron microscopy (immunoEM) as previously described
(14). Cryosections were stained with rabbit IgG specific for either
murine class II (14), murine IgG (315-005-046; Jackson Immu-
nologicals, West Grove, PA), human IgM (309-005-095; Jackson
Immunologicals; 309-005-095), or ovalbumin (RaOVALBUMI;
East Acres Biologicals, Southbridge, MA). Antibody to class II
molecules, anti-ovalbumin, and both anti-Ig antibodies were vi-
sualized with either 1, 5, or 10 nm protein A–gold (14).
 
Steady-state Distribution of the PC-specific huBCR in A20
 
m
 
WT
Cells.
 
A20
 
m
 
WT cells were homogenized and fractionated by
FFE. 200 
 
m
 
l of each FFE fraction, along with 50 
 
m
 
l of homogeni-
zation buffer containing 5% Triton X-100 and 0.5 mg/ml BSA,
was added to a PC–BSA-coated 96-well plate and the samples al-
lowed to bind for 6 h at 4
 
8
 
C. The plates were washed and probed
with rabbit anti–human IgM (1:1,000; 309-005-095; Jackson Im-
munologicals) followed by horseradish peroxidase (HRP)–labeled
goat anti–rabbit IgG (1:1,000; 31462; Pierce Chemical Co.,
Rockford, IL). Bound goat anti–rabbit Ig–HRP was detected by
addition of 200 
 
m
 
l of 0.5 mg/ml 
 
O
 
-phenylenediamine and
0.015% H
 
2
 
O
 
2
 
 in borate buffer. After sufficient time, 50 
 
m
 
l of 1N
HCl was added and the absorbance (OD 490 nm) measured. The
absorbance above background is reported (background 
 
5
 
 
 
z
 
0.200
OD 490 nm).
 
Surface Labeling and Endocytosis.
 
A20
 
m
 
WT cells were collected
by centrifugation and washed two times with PBS. Cells were la-
beled for 15 min at 10
 
8
 
 viable cells/ml in PBS pH 7.5 containing
1 mg/ml sulfosuccinimidyl-6-(biotinamido) hexanoate (NHS–
LC–biotin; Pierce Chemical Company; 21335). The labeling was
quenched by addition of 5–10 vol of 10 mM lysine in PBS. The
labeled cells were pelleted and then washed twice in PBS 0.1%
BSA before incubation at 37
 
8
 
C in complete media containing 1
 
m
 
M PC–OVA (Cells were 
 
.
 
98% viable after labeling, washing,
and incubation).
 
Detection of Biotin-labeled huBCR Molecules in A20
 
m
 
WT FFE
Fractions.
 
FFE fractions (200 
 
m
 
l) from biotin-labeled/PC–OVA
pulsed A20
 
m
 
WT cells were added to NeutrAvidin (50 
 
m
 
g/ml;
31000; Pierce)-coated plates along with 50 
 
m
 
l of homogenization
buffer containing 5% Triton X-100 and 0.5 mg/ml BSA and al-
lowed to bind for 6 h at 4
 
8
 
C. The plate was washed and probed
with rabbit anti–human IgM (1:1,000, 309-005-095; Jackson Im-
munologicals) followed by HRP-labeled goat anti–rabbit Ig
(1:1,000; 31462; Pierce). Bound goat anti–rabbit Ig–HRP was
detected as described above. The absorbance above background is
reported (background 
 
5
 
 
 
z
 
0.100 OD 490 nm).
 
Steady-state Distribution of Ig
 
a
 
 in A20
 
m
 
WT Cells.
 
Individual
A20
 
m
 
WT FFE fractions were concentrated by centrifugation and
analyzed by SDS-PAGE and Western blotting (14) with a rabbit
antiserum raised against intact, full length, bacterially expressed
murine Ig
 
a
 
 (rabbit anti-Ig
 
a
 
, 1:5,000). Binding of rabbit anti-Ig
 
a
 
was detected with HRP-labeled goat anti–rabbit Ig (1:5,000;
31462; Pierce) and enhanced chemiluminescence (ECL; 34080;
Pierce).
 
Immunological Relationship Between Ig
 
a
 
 and p50
 
Ig
 
a
 
.
 
A20
 
m
 
WT low
density membranes (LDM) were separated by preparative SDS-
PAGE and electroblotted onto nitrocellulose. The blot was
probed with rabbit anti-Ig
 
a
 
 (1:1,000) and then extensively
washed. The regions of the blot containing either Iga and p50
 
Ig
 
a
 
were individually excised and bound antibodies eluted with 500
 
m
 
l of 0.1 M glycine, pH 2.5. The eluted antibody was neutralized
with 100 
 
m
 
l, 1.0 M Tris, pH 8.0, and 4.5 ml of blotting buffer.
The affinity-purified antibody was used to probe Western blots of 
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total A20
 
m
 
WT LDM and binding revealed with HRP-labeled
goat anti–rabbit Ig (1:5,000; 31462; Pierce) and ECL (34080;
Pierce).
 
Results and Discussion
 
BCR-mediated Delivery of Antigen to Endosome and CIIV.
 
The murine A20
 
m
 
WT cell line (19) was used as a model
cell for these studies. A20
 
m
 
WT cells express a PC-specific
huBCR as well as an endogenous murine IgG
 
2a
 
 BCR
(muBCR) and the ability of these cells to process and
present antigens via both BCRs has been well characterized
(4, 19). Importantly, A20
 
m
 
WT cells localize only a small
fraction (
 
,
 
10%) of their total class II to intracellular mem-
branes (13, 14), with little class II present in high density,
hydrolase-rich lysosomes (14). Owing to the lack of class II
molecules in the lysosomes of these cells, it is easy to distin-
guish, by FFE, a distinctive population of low density,
novel endocytic vesicles (i.e., CIIV) that are enriched in
newly synthesized class II molecules (14). Moreover, com-
parative analysis of A20 (14, 23) and A20
 
m
 
WT cells (Figs.
1, 2 
 
A
 
, and 4; data not shown) demonstrates that CIIV iso-
lated from both cells possesses the same morphological,
biophysical, biochemical, and immunological characteristics
(e.g., class II–positive, lgp110-negative, 
 
b
 
-Hexosaminidase–
negative multivesicular membrane structures with a charac-
teristic electrophoretic mobility). Importantly, in A20
 
m
 
WT
cells, BCR-mediated antigen processing and peptide load-
ing of class II molecules can occur exclusively in low den-
sity endocytic structures without the involvement of high
density lysosomal structures (13, 14).
If CIIV are involved in BCR-mediated antigen process-
ing, then BCR-internalized antigens should be delivered to
Figure 1. The intracellular
distribution of BCR-internalized
antigen in A20mWT cells.
A20mWT cells were pulsed with 2
mg/ml antigen (i.e., PC–RGG–
125I) for 30 min at 378C before
homogenization and fractionation
by FFE. The distribution of plasma
membrane (PM, major peak of
class II), endosomes and lyso-
somes (E/L, b-Hexosaminidase;
thin solid line), and CIIV (minor,
anodally shifted peak of class II)
are indicated above the graph. (The distribution of class II (broken line)
was determined by quantitative Western blot of every FFE fraction [refer-
ence 14].) Additionally, density gradient analysis of A20mWT cells has dem-
onstrated that, as in A20 cells (14), b-Hexosaminidase–positive lysosomes are
devoid of class II molecules (data not shown), demonstrating that the
b-Hexosaminidase activity present in the CIIV-containing FFE fractions
likely represents contamination by b-Hexosaminidase–positive, class
II–negative lysosomes that were occasionally observed during Immu-
noEM analysis of these FFE fractions (Table 1). The distribution of
huBCR-internalized antigen (i.e., PC–RGG–125I; thick solid line) was de-
termined by counting each fraction in a g counter. (A value of 1.00 5
16,000 cpm above background in the experiment shown.) The major peak
of huBCR-internalized antigen comigrated with markers for endosomes
and lysosomes with a small amount present in CIIV-containing FFE frac-
tions. Illustrated are results representative of three independent experi-
ments.
Figure 2. ImmunoEM localization of BCR-internalized antigen in iso-
lated CIIV as well as endosomes and lysosomes. Bar: 300 nm. (A) Immu-
noEM localization of BCR-internalized antigen in isolated CIIV.
A20mWT cells were pulsed with antigen (i.e., 20 mg/ml PC–OVA) for
30 min at 378C and then fractionated by FFE. Isolated CIIV were then
analyzed by multiple label immunoEM with rabbit anti-class II and 5 nm
protein A–gold followed by rabbit anti-OVA and 10 nm protein A–gold.
Isolated CIIV were found to be doubly positive for both class II and
BCR-internalized antigen (PC–OVA; arrows), indicating that a portion of
the BCR-internalized antigen is delivered to CIIV. The specificity of the
staining for class II molecules and BCR-internalized antigen is demon-
strated by the lack of label over areas of the section that do not contain
vesicular structures. (B and C) ImmunoEM localization of BCR-internal-
ized antigen in isolated endosomes and lysosomes. Endosome/lysosome–
containing FFE fractions from PC–OVA pulsed A20mWT cells were
double labeled for class II and BCR-internalized antigen as in A. BCR-
internalized antigen (PC–OVA; arrows) could be detected in both class II–
negative (B) and class II–positive (C) vesicles.1302 Delivery of BCR–internalized Antigens to Endosomes and Class II Vesicles
CIIV within 30–60 min after BCR-mediated internalization,
the time required for BCR-mediated antigen processing in
A20mWT cells (18). To determine whether this was the
case, A20mWT cells were incubated with PC–RGG–125I
for 30 min under conditions where antigen internalization
and processing occur exclusively via cell-surface huBCR
molecules (18, 19). The antigen-pulsed A20mWT cells were
then homogenized, fractionated by FFE, and the distribu-
tion of huBCR-internalized PC–RGG–125I, as well as that
of markers for plasma membrane (PM), endosomes, lyso-
somes, and CIIV (14), was determined. As shown in Fig. 1,
the vast majority of the huBCR-internalized antigen was
found in FFE fractions that contained endosomes and lyso-
somes (fractions 45–53). However, a small but significant
amount of labeled antigen was present in the anodally shifted
CIIV-containing FFE fractions (fractions 54–58). Thus,
BCR-bound antigen could be found in CIIV-containing
FFE fractions within the time frame during which BCR-
mediated antigen processing is occurring.
This biochemical analysis, along with our previous ob-
servations that CIIV-containing FFE fractions consist al-
most entirely of class II–positive vesicles, strongly suggested
that BCR-internalized antigen can gain access to CIIV. To
demonstrate this point directly, and rule out the possibility
that the BCR-internalized antigen present in the CIIV-
containing FFE fractions was contained exclusively in class
II–negative, b-Hexosaminidase–positive lysosomes, CIIV-
containing FFE fractions from antigen (i.e., PC–OVA)–
pulsed A20mWT cells were examined by multiple label im-
munoEM (14). As shown in Fig. 2 A, huBCR-internalized
antigen (arrow) was present in CIIV isolated from antigen-
pulsed B cells. Additionally, immunoEM analysis of endo-
some/lysosome–enriched FFE fractions demonstrated that
BCR-internalized antigen was present both in class II–neg-
ative endosomes and lysosomes as well as class II–positive
endosomes (Fig. 2, B and C, respectively). Quantitation of
these immunoEM samples (Table 1) revealed that the vast
majority (71–85%) of CIIV were endocytic (i.e., accessible
by BCR-internalized antigen) and that the bulk (58–90%)
of the endocytic vesicles within the CIIV-containing FFE
fractions were class II positive. On the contrary, only 34%
of the endocytic vesicles in the endosome/lysosome–con-
taining FFE fractions were class II–positive endosomes,
with the majority of the antigen-containing vesicles being
class II–negative endosomes and lysosomes.
Table 1. Quantitative ImmunoEM Analysis of FFE Fractions Isolated from Antigen-pulsed A20 mWT Cells
FFE Fraction
Fraction of total
vesicles that contain
class II molecules
Fraction of class II–positive
vesicles* that also contain
BCR-internalized antigen
Fraction of BCR-internalized
antigen-containing vesicles
that are class II positive*
%% %
CIIV 75 71‡ 58‡
E/L 72 21§ 34
CIIV- and endosome/lysosome (E/L)–containing FFE fractions from PC–OVA pulsed A20mWT cells were analyzed by multiple label immunoEM
for the presence of class II molecules and BCR-internalized antigen (i.e., PC–OVA). The percent of vesicles labeled for one or both markers deter-
mined by an unbiased sampling technique (26). For CIIV FFE fractions, a total of 531 vesicle profiles (from four independent experiments) were an-
alyzed. Values are reported as percentages.
*Class II–positive endocytic vesicles represent either CIIV (CIIV FFE fractions) or class II–positive endosomes (endosome/lysosome FFE fractions).
‡In a parallel set of experiments, the distribution of a ligand (i.e., HRP-labeled goat anti-murine IgG) internalized via the endogenous muBCR of
A20mWT cells was determined in CIIV FFE fractions. Quantitative analysis of these samples (292 total vesicle profiles) revealed that 90% of the ves-
icles that contained muBCR-internalized ligand were class II–positive structures (i.e., CIIV) and 85% of CIIV contain muBCR-internalize ligand.
§The nonantigen-containing, class II–positive vesicles in the E/L-containing FFE fractions most likely represent contaminating, class II–containing
Golgi-derived vesicles.
Figure 3. Subcellular distribu-
tion of BCR molecules in
A20mWT cells. (A) Steady-state
distribution of huBCR mole-
cules in A20mWT cells.
A20mWT cells were homoge-
nized, fractionated by FFE, and
the steady-state distribution of
the PC-specific human BCR
was determined by a solid phase
ELISA using PC–BSA-coated
plates. The background absor-
bance (i.e., all reagents added ex-
cept a human BCR-containing
sample; 0.150 OD 490 nm) was
subtracted from the value for
each sample. The major peak of
huBCR (thick solid line) was co-
incident with plasma membrane
(PM) markers (fraction 40).
Some huBCR was also found in
FFE fractions containing endosome–lysosome (b-Hexosaminidase; broken
line) as well as the anodally shifted CIIV (see Fig. 1). Illustrated are results
representative of three independent experiments. (B) Distribution of in-
ternalized huBCR molecules in A20mWT cells. A20mWT cells were
surface labeled with NHS–LC–biotin and then incubated for 0 (thin solid
line), 20 (thick solid line), or 60 (broken line) min at 378C in the presence of
100 nM antigen (i.e., PC–OVA) before homogenization and fraction-
ation by FFE. The distribution of biotin-labeled huBCR was determined
by a solid-phase, human IgM-specific avidin-capture ELISA. After 20
min of internalization at 378C, biotin-labeled huBCR, internalized from
the cell surface, could be detected both in FFE fractions containing CIIV
(fractions 56–65) as well as endosomes and lysosomes (fractions 46–55).
Illustrated are results representative of four independent experiments.1303 Drake et al.
CIIV Contain BCR Molecules Internalized from the Cell
Surface. The presence of BCR-internalized antigen in
CIIV raised the question of whether antigen was delivered
to this compartment while still bound to the BCR or after
dissociation of BCR–antigen complexes. To determine
whether antigen is delivered to CIIV while still bound to
the BCR, we first determined whether BCR molecules
could be found in CIIV at steady-state. To this end,
A20mWT cells were homogenized, fractionated by FFE,
and the distribution of PC-binding huBCR molecules was
determined by an antigen-specific anti–human IgM ELISA.
As shown in Fig. 3 A, most of the PC-binding huBCR was
present in PM-containing FFE fractions (fractions 35–44)
with lower but significant levels also detected in endosome
and lysosome, as well as CIIV-containing FFE fractions
(fractions 45–54 and 55–64, respectively). A similar steady-
state distribution was observed for the endogenous muBCR
as determined by Western blotting (data not shown).
To confirm that the huBCR molecules detected in the
CIIV-containing FFE fractions were actually localized to
CIIV, we performed multiple label immunoEM analysis of
FFE-isolated CIIV for the presence of huBCR molecules.
As shown in Fig. 4, CIIV do contain huBCR molecules
(arrows) at steady-state. Similar analysis of endosome/lyso-
some–containing FFE fractions demonstrated that huBCR
molecules could be found in both class II–positive as well
as class II–negative vesicles in these fractions (data not
shown).
Because we have previously demonstrated that newly
synthesized BCR molecules do not traffic through CIIV
before arrival at the cell surface (14), these results strongly
suggest that the BCR molecules found in CIIV are derived
from the PM by endocytosis and suggest that antigen is de-
livered to this compartment while bound to these internal-
ized BCR molecules. To demonstrate directly that cell sur-
face BCR molecules, internalized in the presence of polyvalent
antigen, are delivered to CIIV, A20mWT were surface la-
beled with biotin, incubated for various times at 378C in
the presence of polyvalent antigen (i.e., PC–OVA), homog-
enized, and then fractionated by FFE. The level of biotin-
labeled (i.e., internalized) huBCR molecules in each FFE
fraction was then determined by a human IgM-specific,
avidin-capture ELISA. As shown in Fig. 3 B, after 20 min
of incubation, internalized huBCR molecules could be de-
tected in CIIV-containing FFE fractions (fractions 53–60)
as well as those enriched in endosomes and lysosomes (frac-
tions 45–52). Surprisingly, even though we had found that,
under similar conditions, a vast majority of the BCR-inter-
nalized antigen was ultimately delivered to endosomes and
lysosomes (see Fig. 1), a significant fraction of the internal-
ized huBCR molecules were found in CIIV-containing
FFE fractions. Therefore, we suggest that a portion, and
possibly all, of the huBCR molecules detected in CIIV by
immunoEM (Fig. 4) were derived from the PM after en-
docytosis, further supporting the contention that antigen is
delivered to CIIV while bound to the BCR. Interestingly,
as suggested by the presence of huBCR molecules in CIIV
isolated from nonantigen-pulsed A20mWT cells, prelimi-
nary analysis of the constitutive endocytosis and trafficking
of the huBCR of A20mWT cells suggests that BCR en-
docytosis and delivery to CIIV can occur in the absence of
antigen cross-linking (Drake, J.R., unpublished results).
Subcellular Distribution of BCR Subunits and Identification of
a Putative CIIV Marker Protein Immunologically Related to Iga.
Although both BCR molecules and BCR-internalized an-
tigen clearly gained access to CIIV, as well as endosomes
and class II–negative lysosomes, the extent to which these
molecules are, or are not, selectively targeted to CIIV re-
mains unclear. To begin to address whether there is any se-
lective targeting of BCR molecules or antigen–BCR com-
plexes to CIIV, we first attempted to determine whether
there is any difference in the subunit composition of the
BCR molecules present in PM, endosome and lysosome,
or CIIV-containing FFE fractions.
To this end, we examined the steady state distribution of
the Iga subunit of the BCR. As shown in Fig. 5 A, the
majority of the 32-kD Iga protein (arrow B) is present in
PM-containing FFE fractions with lesser amounts detected
in endosome–lysosome and CIIV-containing fractions. The
same distribution was also found for the Igb subunit of the
BCR as well as the heavy and light chain subunits of both
the huBCR and muBCR (data not shown), suggesting that
the subunit composition of the BCRs in these compart-
ments is similar. Surprisingly, the anti-Iga antiserum also
recognized a second, 50-kD protein (Fig. 5 A, arrow A)
that appears to be selectively enriched in CIIV-containing
FFE fractions.
To determine whether this 50-kD putative CIIV-marker
protein was immunologically related to Iga (as opposed
to being recognized by antibodies of a second specificity
present in the rabbit anti-Iga antiserum), we affinity-puri-
fied antibodies to both Iga and the 50-kD protein on
Western blots of A20mWT LDM, and tested the specificity
of these purified antibodies. As shown in Fig. 5 B, the un-
fractionated rabbit anti-Iga antiserum recognized both Iga
Figure 4. ImmunoEM localization of huBCR molecules in isolated
CIIV. CIIV were isolated from A20mWT cells by FFE and analyzed by
multiple label immunoEM with rabbit anti-huBCR (anti-human IgM)
and 1 nm protein A–gold followed by rabbit anti–class II and 10 nm pro-
tein A–gold. Isolated CIIV stained for class II and huBCR (arrows). Bar:
100 nm.1304 Delivery of BCR–internalized Antigens to Endosomes and Class II Vesicles
as well as the 50-kD protein present in unfractionated
A20mWT LDM. Although affinity-purified anti-Iga anti-
body failed to recognize the 50-kD protein (occasionally,
reactivity of the affinity-purified anti-Iga toward the 50-
kD protein was observed although the results were variable,
possibly owing to removal of low affinity/highly cross-
reactive antibodies by the affinity purification protocol), af-
finity-purified antibody against the 50-kD protein recog-
nized both Iga as well as the 50-kD protein. Because this
antiserum was originally generated against recombinant
whole murine Iga, these results demonstrate that at least
some anti-Iga antibodies specifically recognize the 50-kD
putative CIIV-marker protein, demonstrating that these
proteins are immunologically related (i.e., that Iga and the
50-kD protein minimally share one cross-reactive epitope).
Additionally, an antiserum raised against the cytoplasmic
tail of Iga (20) also demonstrated cross-reactivity to the 50-
kD protein, suggesting an immunological relationship be-
tween the cytoplasmic tail of Iga and some region of the
50-kD protein (data not shown).
Because the 50-kD putative CIIV-marker protein does
not exhibit a decrease in apparent molecular weight upon
treatment with either endoglycosidase H or F (Drake, J.R.,
unpublished results), we have foregone the more traditional
gp50 designation in favor of p50Iga (the Iga superscript in-
dicates the immunological relationship of the protein to the
Iga subunit of the BCR). Although the structure and func-
tion of p50Iga remains unknown, it is unlikely to represent
a highly modified form of Iga, since it was also detected in
Iga-negative J774 macrophage-like cell line (Drake, J.R.,
unpublished results). Moreover, p50Iga is unlikely to be an
artifact of proteolytic activity because it can be detected in
detergent extracts of whole cells prepared in the presence
of a cocktail of protease inhibitors (Drake, J.R., unpub-
lished results). Additionally, preliminary analysis of J774
cells and the murine B cell hybridoma 2C3E1 (21) suggests
a restricted distribution of p50Iga to CIIV in these cells
(Drake, J.R., and P. Webster, unpublished results).
Considering the presence of p50Iga in the BCR-negative
J774 macrophage-like cell line, p50Iga, unlike Iga, may not
be a component of the BCR protein complex. Correspond-
ingly, preliminary analysis has failed to reveal any physical
association between p50Iga and the BCR of A20mWT cells
(Drake, J.R., unpublished results). Therefore, a more thor-
ough understanding of the possible function of p50Iga will
have to await its eventual purification and sequencing or
cDNA cloning. Interestingly, previous Southern blot anal-
ysis of the murine MB-1 gene (which codes for Iga) indi-
cated the presence of an additional, Iga-related gene (22),
possibly that coding for p50Iga. Most importantly, the iden-
tification of p50Iga as a putative marker for CIIV graphi-
cally demonstrates the unique biochemical nature of these
novel class II-containing vesicles and provides us with a
tool to study their origin, fate, and relationship to other in-
tracellular compartments.
Previously, we demonstrated that in murine B cells, class
II molecules are restricted to relatively early endocytic
compartments (i.e., endosomes and CIIV), with little or no
class II found in high density lysosomes (14). Because pep-
tide–class II complexes have been demonstrated to form
Figure 5. Identification of a putative CIIV-marker protein that is immunologically related to Iga subunit of the BCR. (A) Identification of a 50-kD
protein enriched in CIIV-containing FFE fractions. A20mWT cells were fractionated by FFE and the distribution of markers for plasma membrane (PM,
unshifted class II), endosomes/lysosomes (E/L, b-Hexosaminidase), and CIIV (anodally shifted class II) were determined. The position and size in kilo-
daltons, of the molecular mass standards is indicated at the right. The distribution of the Iga subunit of the BCR was determined by Western blot analysis
using a rabbit antiserum against Iga. The 32-kD Iga protein (indicated by B) was detected at the highest levels in PM-containing FFE fractions contain-
ing and to a lesser extent in fractions containing endosomes–lysosomes and CIIV. Additionally, a 50-kD protein (A) was selectively enriched in the CIIV-
containing FFE fractions (fractions 52–59). The 50-kD protein is also detectable in the unfractionated LDM. Illustrated are results representative of five
independent experiments. (B) The 50-kD putative CIIV-marker protein is immunologically related to the Iga subunit of the BCR. Preparative Western
blots of A20 LDMs were probed with the rabbit anti-Iga antiserum and washed. The antibodies against Iga and the 50-kD protein were affinity purified
by excising the regions of the blot containing the anti-Iga and anti-50-kD proteins (and bound antibodies) and then eluting the bound antibodies. The
affinity-purified antibodies, as well as uncut antiserum, were then used to probe a Western blot of unfractionated LDM. The uncut serum (lane 1) recog-
nized both the 32-kD Iga (arrow B) as well as the 50-kD protein (arrow A) in the LDM. Although the affinity-purified anti-Iga (lane 2) did recognize
Iga, it failed to recognize the 50-kD protein present in the LDM. (In some experiments, the affinity-purified anti-Iga antibodies did demonstrate reactiv-
ity towards the 50-kD protein.) Importantly, antibodies affinity purified on the 50-kD protein (lane 3) recognized both the 32-kD Iga protein (arrow B)
as well as the 50-kD protein (arrow A), indicating an immunological relationship between these two proteins. (Immunoreactivity of the affinity-purified
anti-50-kD antibodies against Iga was observed in every experiment.) Illustrated are results representative of three independent experiments.1305 Drake et al.
only in low density (i.e., nonlysosomal) compartments in
these cells (13, 14), the presence of BCR-internalized anti-
gen in both class II–positive endosomes as well as CIIV
suggests that antigen processing and class II peptide loading
may occur at either or both of these sites. Given the pre-
dominant role of newly synthesized class II molecules in
BCR-mediated antigen processing and presentation (6–8)
and the fact that CIIV are an intermediate in the pathway
of transport of newly synthesized class II molecules to the
cell surface (14, 23), our results strongly suggest a role for
CIIV in BCR-mediated antigen processing and class II
peptide loading.
Why might B cells possess a novel endocytic compart-
ment for the processing of BCR-internalized antigens? In
contrast with endosomes, lysosomes, and MIIC, which
readily accumulate nonselectively internalized fluid phase
endocytic tracers (10, 24), CIIV do not readily accumulate
proteins internalized by fluid phase endocytosis (14). Within
endosomes, lysosomes, and MIIC, the vast excess of nonanti-
genic peptides (i.e., peptides derived from the proteolytic
degradation of fluid phase plasma proteins) may effectively
compete with antigenic peptides (i.e., peptides derived
from BCR-internalized antigen) for binding to class II
molecules, preventing the efficient formation of antigenic
peptide–class II complexes within these compartments.
The absence of these nonantigenic peptides from CIIV
may allow for more efficient formation of antigenic pep-
tide–class II complexes in these vesicles. Additionally, be-
cause peptide loading onto class II is a relatively slow pro-
cess (25), the relatively slow transport of newly synthesized
class II molecules through CIIV, with class II molecules re-
siding in CIIV for up to 2 h (14), may provide the neces-
sary time for the loading of these class II molecules with
antigen-derived peptides.
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